Abstract
The Hepatocyte Growth Factor is a strong mitogenic factor and seems to play important role in tumor angiogenesis. The purpose of this study was to analyse the plasma concentration of this factor in patients treated surgically because of intracranial tumors. The study included 47 patients, both sexes treated surgically for intracranial tumors and 30 adult volunteers of both sexes, without cancer diagnosis. In study group 4 measurements of plasma HGF were taken: measurement 1: within 24 hours to 1 hour before the operation (preoperative), measurement 2: on the first day after the operation, i.e. after 24 hours, measurement 3: between the third and fifth day following the treatment, i.e. within 72–120 hours, and measurement 4: on the seventh day after the operation, i.e. after 840 hours. In control group only one measurement was taken. The distribution of the analyzed parameters was different from the normal distribution, therefore nonparametric statistics were used. The result values are presented in the form of a median (Me). The analysis revealed that HGR plasma levels in the patients with intracranial tumors in all 4 measurements (Me1 = 543.16 pg/ml, Me2 = 762.59 pg/ml, Me3 = 819.82 pg/ml, Me4 = 804.82 pg/ml) in the perioperative period were elevated in comparison to healthy subjects (Me = 361.04 pg/ml). The association has been shown to exist between postoperative HGF plasma levels and the clinical condition of patients with intracranial tumors (p = 0.0342). Postoperative HGF levels correlated negatively with the patients' postoperative condition. It was also found that in patients with supratentorial tumors HGF plasma levels were higher (Me = 557.74 pg/ml) in comparison to patients with posterior fossa tumors (Me = 325.00 pg/ml). These results suggest increased angiogenic and mitogenic activity in patients with intracranial tumors and its even greater intensity in the postoperative period. Greater angiogenic activity appears to occur in patients with supratentorial tumors.
Highlights
The Hepatocyte Growth Factor (HGF) is a protein that exhibits strong mitogenic properties— one that regulates the development and regeneration of tissues [1]
It was found that preoperative plasma levels of the HGF in brain tumor patients were higher (Me = 543.16 pg/ml) than the levels found in healthy subjects (Me = 361.04 pg/ml)
Significant differences were shown to exist between the preoperative measurement of HGF level and each of the three postoperative measurements (Friedman test: measurement 1 vs. measurement 2—p = 0.001, measurement 1 vs. measuring 3—p = 0.001, and measurement 1 vs. measurement 4—p = 0.001)
Summary
The Hepatocyte Growth Factor (HGF) is a protein that exhibits strong mitogenic properties— one that regulates the development and regeneration of tissues [1]. It is produced by all cells of mesenchymal origin. Binding of HGF to c-Met activates metabolic pathways, resulting in an increase in the synthesis of metalloproteinase-1 and stromyelisine-1, responsible for the degradation of the basement membrane of the endothelial cells and the extracellular matrix. HGF stimulates mitotic division in glial cells, endothelial cells and in the tumor cells themselves, by binding to its MET receptor [1,3]. It was proven that in patients with more advanced breast and colorectal cancers and the presence of metastases, HGF levels were significantly higher than in patients with less advanced proliferative process [6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
